The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders
Yiwen Ma, Shisheng Wang, Xiaorui Li, Xiangyu Guo, Cui Jiang, Tao Sun · 2026
Read The novel oleanolic acid derivative ZQL-4c modulates trastuzumab resistance in HER2+ breast cancer by inhibiting SCD-mediated lipid metabolism disorders by Yiwen Ma, Shisheng Wang, Xiaorui Li, Xiangyu Guo, Cui Jiang, Tao Sun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13551784.txt.
Description
Yiwen Ma, joined by five colleagues, authored a 2026 study of a new compound against breast cancers that resist the antibody drug trastuzumab. About a fifth of breast cancers are HER2-positive and over a third of treated patients relapse through resistance. Working with chemists at Dalian University of Technology, the team synthesized ZQL-4c, a derivative of oleanolic acid from plants, aimed at a fat-metabolism enzyme called SCD.
By blocking that enzyme, the compound disrupts lipid handling in resistant cells and pushes them into a toxic, self-killing state the authors call lipotoxicity-mediated apoptosis. The abstract frames the work as an attractive future direction rather than a proven therapy. Such metabolism-targeted drugs, the authors suggest, could complement existing HER2 treatments when resistance emerges.
Catalog record
| CREATOR | Yiwen Ma, Shisheng Wang, Xiaorui Li, Xiangyu Guo, Cui Jiang, Tao Sun |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37999 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |